Clinical Trials Logo

Filter by:
NCT ID: NCT00206141 Completed - Depression Clinical Trials

Seroquel in Bipolar Depression Versus Lithium

Start date: August 2005
Phase: Phase 3
Study type: Interventional

This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to 52 with quetiapine fumarate (Seroquel) compared to placebo.

NCT ID: NCT00206128 Completed - Schizophrenia Clinical Trials

Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine that the efficacy of the sustained release (SR) formulation of quetiapine (Seroquel) is not inferior to the immediate release (IR) formulation. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00205777 Completed - Osteoporosis Clinical Trials

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

Start date: December 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.

NCT ID: NCT00196716 Completed - Fabry Disease Clinical Trials

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Start date: June 2003
Phase: Phase 2
Study type: Interventional

People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. This enzyme helps to break down and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In people with Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because alpha-galactosidase A is not present, or is present in small quantities. The build up of glycolipid levels (also referred to as "globotriaosylceramide" or "GL-3") in these tissues is thought to cause the clinical symptoms that are common to Fabry disease. Symptoms commonly appear during childhood with pain in the hands and feet. This trial is designed to evaluate the efficacy of a lower dose of Fabrazyme in patients who initially received 1.0 mg/kg every 2 weeks of Fabrazyme by investigating if the achieved clearance of glycosphingolipid deposits in the vascular endothelium of the kidney can be maintained at a lower dose.

NCT ID: NCT00191126 Completed - Clinical trials for Non-Small Cell Lung Cancer

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC

Start date: September 2000
Phase: Phase 3
Study type: Interventional

Preoperative chemotherapy is considered to play a role in early stage non small cell lung cancer (NSCLC) .The use of preoperative Cisplatin/Gemcitabine chemotherapy has proven feasible and without excessive morbidity or mortality in the Phase II setting. The aim of the present Phase III study is to determine whether 3 cycles of preoperative chemotherapy with Cisplatin/Gemcitabine improves progression free survival of NSCLC patients versus surgery alone. Postoperative chemotherapy will not be utilized in this Phase III trial.

NCT ID: NCT00189813 Completed - Clinical trials for Irritable Bowel Syndrome

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.

NCT ID: NCT00179777 Completed - Clinical trials for Diabetes Mellitus, Type 1

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

TRIGR
Start date: May 6, 2002
Phase: N/A
Study type: Interventional

The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The TRIGR study was targeted at newborns who are at genetic risk for type 1 diabetes because their mother, father and/or full sibling has type 1 diabetes. All families were encouraged to breast feed their infants for as long as possible. Prior to birth, the child was randomly assigned to receive one of two infant formulas, should formula be required prior to 8 months of age. The study determined whether weaning to a possibly protective infant formula decreases these children's chances of developing diabetes - as it does in the animal models for diabetes.

NCT ID: NCT00175877 Completed - Clinical trials for Rheumatoid Arthritis

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Start date: June 2005
Phase: Phase 3
Study type: Interventional

An open ended study in which patients who completed the double-blind study CDP870-027 [NCT00152386] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).

NCT ID: NCT00174993 Completed - Diabetes Mellitus Clinical Trials

Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

PROactive
Start date: May 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes.

NCT ID: NCT00174720 Completed - Asthma Clinical Trials

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Start date: September 2005
Phase: Phase 3
Study type: Interventional

To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.